Clinical Trial

Trial Protocol ID USOR 22297_D926QC00001

Trial Description

A Phase III, Open-Label, Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Cheomotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer 

View on ClinicalTrials.gov

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Investigator

  • Jeanine L Werner, MD

Disease Types

Sponsor

  • AstraZeneca

ClinicalTrials.gov NCT ID

  • NCT06112379